Publications by authors named "James Mier"

Claim this Profile
R
Retraction Note to: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells.
David J Panka, Qingjun Liu, Andrew K Geissler, James W Mier

Mol Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction Note to: Differential modulatory effects of GSK-3b and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Qingjun Liu, James W Mier, David J Panka

Mol Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Vicky Makker, Matthew H Taylor, Carol Aghajanian, Ana Oaknin, James Mier

J Clin Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors.
Rohit Thummalapalli, Johannes C Melms, James Mier, Benjamin Izar

Melanoma Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors.
Ruchi Saxena, Yan Wang, James W Mier

Melanoma Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction: The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells.
David J Panka, Wei Wang, Michael B Atkins, James W Mier

Cancer Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma.
Daniel C Cho, Matthew B Cohen, David J Panka, Michael Collins, Musie Ghebremichael, James W Mier

Clin Cancer Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.
Rebecca Karp Leaf, Christopher Ferreri, Deepa Rangachari, James Mier, Wesley Witteles

Am J Hematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Vicky Makker, Drew Rasco, Nicholas J Vogelzang, Marcia S Brose, Allen L Cohn, James Mier

Lancet Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The tumor microenvironment in renal cell cancer.
James W Mier

Curr Opin Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).
Sneha Berry, Nicolas Giraldo, Peter Nguyen, Benjamin Green, Haiying Xu, James Mier

J Immunother Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of cell-free tumor DNA sequencing from the cerebrospinal fluid to guide treatment in a patient with primary leptomeningeal melanoma: A case report.
Johannes C Melms, Ka-Wai Ho, Rohit Thummalapalli, Janice Tyler, Titus Josef Brinker, James Mier

Mol Clin Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Ryan J Sullivan, Jeffrey R Infante, Filip Janku, Deborah Jean Lee Wong, Jeffrey A Sosman, James W Mier

Cancer Discov· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.
Amy K Erbe, Wei Wang, Jacob Goldberg, Mikayla Gallenberger, KyungMann Kim, James W Mier

Clin Cancer Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.
John Sarantopoulos, Alain C Mita, Aiwu He, James L Wade, Chung-Tsen Hsueh, James Mier

Cancer Chemother Pharmacol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.
Wei Wang, Amy K Erbe, Mikayla Gallenberger, KyungMann Kim, Lakeesha Carmichael, James Mier

Cancer Immunol Immunother· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
Jeffrey J Wallin, Johanna C Bendell, Roel Funke, Mario Sznol, Konstanty Korski, James Mier

Nat Commun· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
Xiaoen Wang, Nicolas Solban, Prateek Khanna, Marcella Callea, Jiaxi Song, James W Mier

Oncotarget· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel drugs that target the metabolic reprogramming in renal cell cancer.
Johannes C van der Mijn, David J Panka, Andrew K Geissler, Henk M Verheul, James W Mier

Cancer Metab· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib activates Axl signaling in renal cell cancer.
Johannes C van der Mijn, Henk J Broxterman, Jaco C Knol, Sander R Piersma, Richard R De Haas, James W Mier

Int J Cancer· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
Johannes C van der Mijn, James W Mier, Henk J Broxterman, Henk M Verheul

Drug Resist Updat· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.
Ryan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, Julie Aldridge, Anita Giobbie-Hurder, James W Mier

Oncologist· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.
Liang Zhang, Xiaoen Wang, Andrea J Bullock, Marcella Callea, Harleen Shah, James W Mier

Clin Cancer Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitors in the treatment of metastatic melanoma.
James W Mier

Clin Ther· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
David F McDermott, Su-Chun Cheng, Sabina Signoretti, Kim A Margolin, Joseph I Clark, James W Mier

Clin Cancer Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis